Download Brimo
Demarcus Smith
Purpose : Brimonidine tartrate, an alpha-2 adrenergic receptor agonist, has been shown to prevent retinal damage in several animal models. The purpose of this study was to evaluate the effects of brimonidine formulated in a biodegradable drug delivery system on sVEP in eyes with glaucomatous optic neuropathy (GON) induced by chronic ocular hypertension.
The neuroprotective properties of brimonidine is well known, both in in vitro and in vivo models and topical applications play an important role in delaying glaucoma progression. In this Phase IIb study (BEACON), the safety and efficacy of intravitreally delivered extended release brimonidone and its effects on geographic atrophy lesion size over 24 months were studied.
400ug of brimonidine is injected using a 25Ga injector akin to the Ozurdex injector on a q3 month schedule. Only patients with GA measuring between 1.25mm2 to 18mm2 were enrolled. 303 patients were randomized to receive sham or brimo DDS treatment. The 2 groups were well balanced and the mean lesion size prior to beginning of therapy was 5.48mm2 and 5.16mm2 respectively with a yearly progression of 1.6mm2.
dca57bae1f